Objective-TFEB (transcription factor EB) was recently reported to be induced by atheroprotective laminar flow and play an anti-atherosclerotic role by inhibiting inflammation in endothelial cells (ECs). This study aims to investigate whether TFEB regulates endothelial inflammation in diabetic db/db mice and the molecular mechanisms involved. Approach and Results-Endothelial denudation shows that TFEB is mainly expressed in ECs in mouse aortas. Western blotting shows TFEB total protein level decreases whereas the p-TFEB S142 (phosphorylated form of TFEB) increases in db/db mouse aortas, suggesting a decreased TFEB activity. Adenoviral TFEB overexpression reduces endothelial inflammation as evidenced by decreased expression of vascular inflammatory markers in db/db mouse aortas, and reduced expression of a wide range of adhesion molecules and chemokines in human umbilical vein ECs. Monocyte attachment assay shows TFEB suppresses monocyte adhesion to human umbilical vein ECs. RNA sequencing of TFEB-overexpressed human umbilical vein ECs suggested TFEB inhibits NF-κB (nuclear factor-kappa B) signaling. Indeed, luciferase assay shows TFEB suppresses NF-κB transcriptional activity. Mechanistically, TFEB suppresses IKK (IκB kinase) activity to protect IκB-α from degradation, leading to reduced p65 nuclear translocation. Inhibition of IKK by PS-1145 abolished TFEB silencing-induced inflammation in human umbilical vein ECs. Lastly, we identified KLF2 (Krüppel-like factor 2) upregulates TFEB expression and promoter activity. Laminar flow experiment showed that KLF2 is required for TFEB induction by laminar flow and TFEB is an anti-inflammatory effector downstream of laminar flow-KLF2 signaling in ECs.
V ascular complications of diabetes mellitus increase the risk of developing atherosclerotic diseases and are the major causes of mortality and disability. 1 Chronic vascular inflammation in diabetes mellitus is closely associated with atherogenesis and subsequent development of coronary artery and cerebrovascular diseases. 2, 3 Therefore, therapies with anti-inflammatory effects are believed to alleviate vascular complications in diabetic patients. 4 The NF-κB (nuclear factor-κB) pathway is an important signaling cascade that controls proinflammatory gene expression in multiple cell types. 5 The NF-κB family members (including RelA/p65, RelB, c-Rel, p50/NFKB1, and p52/NFKB2) form either homodimers or heterodimers to transcribe gene expression in the nucleus. 6 In the unstimulated state, the IκB (inhibitor of NF-κB) binds to NF-κB dimers in the cytoplasm to render NF-κB inactive. 7 On stimulation by proinflammatory signals of immunoreceptors on the cell surface, the activated IKKs (IκB kinases) phosphorylate IκB proteins on serine residues. [5] [6] [7] Phosphorylation of IκBs leads to their degradation in the proteasome and release of active NF-κB dimers for nuclear translocation and target gene induction. 8 Hyperactivation of IKK-β and NF-κB is implicated in inflammatory responses in various tissues during obesity and diabetes mellitus, 9, 10 including the vasculature. 3 Nevertheless, the regulatory mechanisms of NF-κB activity in diabetes mellitus are still unclear.
Endothelial cells (ECs) rapidly respond to changes in hemodynamic forces or blood flow patterns, and interact with circulating substances. 11 Hyperglycaemia and hyperlipidemia in diabetes mellitus induce endothelial inflammation manifested by increased endothelial expression of inflammatory markers such as VCAM1 (vascular cell adhesion molecule 1) and MCP1 (monocyte chemoattractant protein 1), 1, 3 which recruit monocytes to infiltrate the vascular wall. TFEB (transcription factor EB) is the master regulator governing gene regulation of autophagy and lysosomal biogenesis. 12, 13 Recently, TFEB was shown to play an anti-atherosclerotic role by inhibiting endothelial inflammation.
14 However, the mechanisms of TFEB-related anti-inflammatory effects remain largely unclear, and it is yet to be explored whether TFEB controls NF-κB activity in ECs.
Type 2 diabetes mellitus is a metabolic disorder characterized by insulin resistance and hyperglycemia. The excessive glucose and insulin in diabetes mellitus may negatively regulate TFEB nuclear translocation and activity. 12, 15 By contrast, the anti-inflammatory laminar shear stress (LSS) induces TFEB expression. 14 In this report, we found that TFEB activity is decreased in diabetic mouse vascular endothelium and overexpression of TFEB is anti-inflammatory in diabetic db/db mice. TFEB inhibits IKK activity and increases IκBα level to suppress NF-κB activity in ECs. We also identified KLF2 (Krüppel-like factor 2), an inducible anti-inflammatory transcription factor by LSS, 16 as a required upstream regulator of TFEB expression. The present results suggest that upregulation of TFEB is protective against vascular inflammation in diabetes mellitus.
Materials and Methods
The authors declare that all supporting data are available within the article (online-only Data Supplement).
Animals
The use of animals and research protocols in this study were approved by the Laboratory Animal Experimentation Ethical Committee, Chinese University of Hong Kong and confirmed with the Guideline for the Care and Use of Laboratory Animals. Ten to sixteen weeks old male C57BL/6J mice, db/m + and db/db mice were provided by Chinese University of Hong Kong Laboratory Animal Service Center and housed in a temperature-controlled room (22°C-24°C) with a 12-hour light/dark cycle and fed with standard diet and had free access to water. 
Chemicals and Antibodies

Cell Culture
Human umbilical vein endothelial cells (HUVECs) from Lonza (CC-3317) were cultured in EGM (DMEM/F12 supplemented with 20% FBS, EC growth supplement (50 μg/mL), and 100 U/mL penicillin plus 100 μg/mL streptomycin) in 37°C incubator. HEK293A and HEK293T from ATCC were cultured in high glucose-containing DMEM supplemented with 10% FBS. RPMI-1640 medium plus 2-mercaptoethanol to a final concentration of 0.05 mmol/L and FBS to a final concentration of 10% was used for culture of THP-1 (ATCC TIB-202) cells.
Recombinant Adenoviral and Lentiviral Vectors
Adenovirus encoding full-length mouse Tfeb CDS (NM_011549.3) was constructed with Gateway Cloning System according to the manufacturer's protocol. Correct construct was digested by Pac I enzyme before transfection into HEK293A cells until 80% cytopathic effect was observed. PEG6000 precipitation method was used for the condensation of adenovirus. Adenovirus-TFEB (Ad-TFEB) or Ad-GFP (10 10 pfu/mouse) were administered to mice via tail vein injection and 5 days later mice were euthanized. Ad-KLF2 and adenovirus short hairpin RNA targeting KLF2 (Ad-shKLF2; CGGCACCGACGACGACCTCAA) were generated using the same method.
Human TFEB shRNA sequence (ATGTCCTTGGCTACATCAA) was cloned to the GV248 plasmid backbone. Lentivirus encoding TFEB shRNA (LV-TFEB-shRNA [shTFEB]) was generated by cotransfection of GV248, PMD2.0, and PSPAX to HEK293FT cells for 48 hours. The supernatant containing LV-shTFEB was collected and purified.
Ex Vivo Culture of Mouse Aortas
Twelve-week old male db/m + and db/db mice were euthanized by CO 2 . After plasma collection, the aortas were dissected out, and surrounding connective tissues were removed, and then placed in ice-cold Krebs solution (in mmol/L: 119 NaCl, 4.7 KCl, 2.5 CaCl 2 , 1 MgCl 2 , 25 NaHCO 3 , 1.2 KH 2 PO 4 , and 11 D-glucose). Each aorta was cut into ring segments that were cultured in DMEM supplemented with 40% plasma collected from db/m + and db/db mice. Following treatment with Ad-GFP or Ad-TFEB for 24 hours, protein or RNA were extracted from the aortic rings for further experiments.
Dual Luciferase Activity Assay
pGL3-NF-ĸB reporter plasmid and TFEB promoter reporter plasmid containing firefly luciferase gene were used. The purified luciferase plasmid (2 μg) was transiently transfected into HUVECs or HEK293T cells using the Neon Transfection System (Thermo Fisher Scientific). The indicated reporter constructs were cotransfected with the internal control Renilla reporter plasmid (40 ng, Promega). Luciferase activity was determined by using the Dual-Luciferase Reporter Assay System (Promega). 
Nonstandard Abbreviations and Acronyms
In Vitro Shear Stress Study
Ibidi flow system (IBIDI, Germany) was used to generate LSS (12 dyn/ cm 2 ). The assembly of flow system and computer control program were set up according to manufacturer's instruction. Briefly, HUVECs at a density of 5×10 5 cells were seeded onto autoclaved glass slides (75×38 mm; Corning) that had been precoated with fibronectin (50 μg/mL) and cultured in 20% FBS-EGM before mounted to the flow chamber. During LSS, the medium was replaced with EGM supplemented with 2% FBS for 24 hours. For LSS-induced TFEB expression, shear force was applied for 24 hours unless otherwise mentioned.
17
RNA Sequencing
HUVECs were transduced with Ad-TFEB and Ad-GFP for 24 hours and then harvested for RNA extraction using RNeasy Mini Kit (Qiagen, Germany). The extracted RNA samples were sent to Macrogen, Inc (South Korean) for RNA-sequencing analysis. P<0.05 and fold change >1.5 was used as a threshold for differential regulated genes. DAVID tools were used for the NF-ĸB, and oxidative stress pathways enrichment analysis and ClueGo was used for the Gene Ontology analysis.
Real-Time Polymerase Chain Reaction
Cellular or tissue samples were homogenized and lysed in the Trizol reagent. Total RNAs were isolated, and 2 µg RNA was reversely transcribed using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 4368813). Quantitative polymerase chain reaction was ran on the ViiA TM7 real-time polymerase chain reaction system (Applied Biosystems) with GAPDH as an internal control. Gene expression was analyzed by the comparative C T method. Please refer to online-only Data Supplement for the DNA sequences of primers.
Western Blotting and Immunoprecipitation
Cells or tissues were homogenized in radio immunoprecipitation assay lysis buffer consisting of radio immunoprecipitation assay solution, protease inhibitors and phosSTOP phosphatase inhibitors (Roche Life Sciences, 04906845001). The proteins were separated by acrylamine gel before transferred to polyvinylidene fluoride (Millipore) membrane. Before incubation in primary antibodies at 4°C overnight, the membranes were blocked with 3% BSA dissolved in 1×tris-buffered saline tween 20 buffer. The membranes were washed in tris-buffered saline tween 20 and subsequently incubated with corresponding secondary antibodies conjugated with horseradish peroxidase (DakoCytomation) for 1 hour at room temperature. The membranes were washed again in tris-buffered saline tween 20 before development with enhanced chemiluminescence detection on X-ray films. For immunoprecipitation, protein lysates of db/m + and db/db mouse aortas were immunoprecipitated with TFEB antibody, followed by Western blotting with anti-Ubiquitin antibody.
En face and Immunofluorescence Staining
Segments of thoracic aortas or cultured HUVECs were fixed in 4% paraformaldehyde and permeabilized by 0.01% Triton X-100. The segments were blocked by 5% normal donkey serum in PBS at room temperature and then incubated with primary antibody or IgG control antibody at 4°C overnight, followed by AlexaFluor secondary antibodies for 2 hours at room temperature in dark. Nuclei were counterstained with 4', 6-diamidino-2-phenylindole (DAPI). For aortas, the segments were cut open longitudinally, and the cut-open aortas were placed upside down between 2 coverslips with the endothelial layer facing upwards. Fluorescent images were captured by Fluoview FV1000 laser scanning confocal system (Olympus, Tokyo, Japan).
Monocyte Attachment Assay
THP-1 cells were labeled with 1 µmol/L Cell Tracker Red (Molecular Probes; Invitrogen) in serum-free RPMI 1640 medium and washed in PBS. HUVECs were pretransduced with shTFEB for 72 hours or Ad-TFEB followed by IL-1β for 24 hours. Thereafter, cells were washed in PBS to remove cell debris, and 2 mL of labeled THP-1 monocytes suspension (10 5 cells/mL) was added to HUVECs. Nonadherent THP-1 cells were removed, followed by gentle wash of the cells in PBS and finally in fresh EGM medium. The THP-1-bound HUVECs were visualized under a bright-field and fluorescence microscopy.
Statistical Analysis
Results represent mean±SEM of n separate experiments. The data were analyzed using GraphPad Prism (Version 6, CA). Gene and protein expression was normalized to GAPDH. Normality and equal variance tests were performed for all variables before further analysis. For data passed equal variance test, unpaired t test was used to analyze differences between 2 groups 1-way ANOVA followed by Tukey multiple comparison test was used for analysing the differences between multiple groups. If a normal distribution could not be achieved, nonparametric tests were used. Mann-Whitney test was applied for 2 independent groups and Kruskal-Wallis test followed by Dunn, multiple comparison test, was used for comparing multiple groups. P <0.05 was considered as statistically different.
Results
TFEB Activity Decreases in Aortic Endothelium from Diabetic db/db Mice
To investigate the role of TFEB in regulation of vascular inflammatory responses in diabetes mellitus, we first determined the expression abundance of TFEB in aortas isolated from C57/BL6 mice. Denudation of endothelium in mouse aortas significantly reduced expression of both TFEB and p-TFEB ( Figure 1A and 1B). The removal of endothelium was confirmed by markedly reduced level of eNOS, an EC marker whereas the expression of α-SMA (α-smooth muscle actin), a VSMC (vascular smooth muscle cell) marker, was detected in both EC-denuded and -intact aortas ( Figure 1A and 1B). This indicates that TFEB is mainly expressed in ECs in mouse aortas. The mRNA level of Tfeb increases in ECs of aortas from diabetic db/db mice compared with nondiabetic db/m + mice ( Figure 1C ). The experiments on HUVECs treated with several chemical risk factors related to diabetes mellitus showed that only insulin treatment increases TFEB mRNA level whereas others have no effect (Figure II in the onlineonly Data Supplement). These results suggest that TFEB gene transcription is likely to be enhanced by hyperinsulinemia in diabetic mice. The increased expression of vascular proinflammatory markers, including Icam1, Ccl2, Sele, and Vcam1, mainly takes place in aortic ECs from db/db mice. Lack of Pecam1 mRNA expression confirms successful removal of ECs ( Figure I in the online-only Data Supplement).
In contrast to increased mRNA expression, TFEB total protein level decreased whereas the phosphorylated TFEB at Serine142 (p-TFEB S142 reflects TFEB cytoplasmic retention and inactivation) increased in db/db mouse aortas ( Figure 1D through 1F). In addition, TFEB immunoprecipitation followed by detection using ubiquitin antibody showed an increased ubiquitination of TFEB in db/db mouse aortas ( Figure II in the online-only Data Supplement). These data indicate a decreased TFEB activity and expression in aortic endothelium in db/db mice. To further validate the reduced TFEB activity in db/db mice, we en face immunostained TFEB expression in ECs and found that the nuclear amount of TFEB decreased in db/db mice ( Figure 1G and 1H). Consistent with in vivo observation, treatment of HUVECs with proinflammatory cytokine IL-β increased p-TFEB level but decreased total TFEB expression ( Figure 1I and 1J and Figure I in the online-only Data Supplement). Insulin treatment also induced a transient increase of p-TFEB level although high glucose and LPC had no effect ( Figure III in the online-only Data Supplement). Taken together, the elevated p-TFEB level in db/db mouse aortas is likely attributed to increased proinflammatory cytokines such as IL-1β and hyperinsulinemia in these mice.
TFEB Overexpression Inhibits Expression of Vascular Inflammatory Markers in db/db Mice
Given that TFEB activity decreases in db/db mouse aortic ECs, we overexpressed TFEB in diabetic db/db mice by tail-vein injection of Ad-TFEB. Five days after injection, we sacrificed the mice and isolated aortas. TFEB mRNA and protein levels in livers increased significantly in TFEB overexpressing db/db mice ( Figure IV in the online-only Data Supplement). Western blotting data showed that ectopic TFEB expression reduced VCAM1 levels in db/db mouse aortas, where TFEB protein level was increased by Ad-TFEB administration (Figure 2A and 2B; Figure IV in the online-only Data Supplement). The mRNA levels of 2 key vascular adhesion molecules Icam1 and Vcam1 were downregulated by Ad-TFEB in aortas of db/db mice ( Figure 2C ). Next, we performed organ culture experiment to explore whether TFEB has a direct anti-inflammatory effect in vasculature. Consistent with the in vivo results, TFEB overexpression inhibited VCAM1 protein expression in db/db mouse aortas ( Figure 2D and 2E) . The increased mRNA expression of Icam1 and Vcam1 in db/db mouse aortas was reduced by Ad-TFEB to levels comparable to those in db/m + mouse aortas ( Figure 2F ). Taken together, both in vivo and ex vivo TFEB overexpression produce an anti-inflammatory effect in aortas of diabetic mice.
TFEB Inhibits Expression of Adhesion Molecules and Monocyte Adhesion to HUVECs
To investigate the potential role of TFEB in suppression of monocyte adhesion to ECs, we performed monocyte attachment assay. Ad-TFEB reversed IL-1β-induced attachment of THP-1 cells to HUVECs ( Figure 3A and 3B) . By contrast, 
TFEB Overexpression Suppresses NF-κB Transcriptional Activity in HUVECs
TFEB has recently been reported to exert anti-inflammatory effects, partially mediated through its anti-oxidative stress property in ECs, 14 suggesting that other unknown mechanisms may also exist. To identify genes involved in inflammatory pathways that are regulated by TFEB, we analyzed mRNA expression profile by RNA sequencing (RNA-seq) in HUVECs transduced with Ad-TFEB. Consistent with the report by Lu H et al 14 TFEB indeed induces antioxidant genes including HMOX1 and SOD2 and inhibits superoxide generator NOX4 in HUVECs ( Figure VI in the online-only Data Supplement). Gene ontology analysis for biological process indicates that TFEB is involved in regulation of EC and leukocyte migration ( Figure 4A ). DAVID KEGG enrichment analysis revealed a strong enrichment of inflammatory pathways, including Cytokine-Cytokine receptor interaction, TNF (tumor necrosis factor) signaling pathway and Hippo signaling pathway ( Figure 4A ). Heatmap for RNA-seq results showed that TFEB regulates the expression of a large number of genes involved in NF-κB pathway ( Figure 4B ).
To test whether TFEB affects transcription of inflammatory genes, we used luciferase reporter vector for NF-κB to measure NF-κB transcriptional activity. The results showed that Ad-TFEB reduced basal and IL-1β-induced NF-κB transcriptional activity ( Figure 4C ), thus confirming the suppressive effect of TFEB on NF-κB. We also verified the mRNA expression of CCL2, SELE, IL6, CXCL8, and CXCL1 by quantitative polymerase chain reaction and found that TFEB strongly inhibits the expression of these genes ( Figure 4D ). Furthermore, we measured p65 nuclear translocation in response to IL-1β in TFEB overexpressed HUVECs. Immunofluorescence staining of p65 in HUVECs after IL-1β treatment showed that TFEBinduced p65 cytoplasmic retention ( Figure 4E and 4F) . 
TFEB Protects IκBα from IKK-Induced Degradation to Inhibit NF-κB
To elucidate the key mediators through which TFEB inhibits NF-κB signaling, we determined TFEB-regulated genes upstream of NF-κB using quantitative polymerase chain reaction screening and found that TFEB inhibited multiple activators of NF-κB ( Figure 5A and Figure VI in the online-only Data Supplement). Knockdown of TFEB increased expression of BIRC2, BIRC3, IRAK4, RIP1, TIRAP, and MYD88 ( Figure 5B ), which are likely to be transcriptionally repressed by TFEB to mediate the suppression of NF-κB activity. Based on these results, we hypothesized that TFEB might regulate IKK activity since the above-mentioned 6 genes all transduce proinflammatory signals to converge on IKKs, [18] [19] [20] [21] [22] which phosphorylate IκBα to liberate NF-κB nuclear localization. 23 Therefore, we next measured phosphorylated levels of IKKα/β (Serine176/178) and IκBα (Serine32) and IκBα expression in HUVECs treated with IL-1β for 30 min. Compared with control, IL-1β strongly induced phosphorylation of IKKα/β and suppressed IκBα level ( Figure 5C and Figure VII in the online-only Data Supplement). TFEB overexpression did not affect basal IκBα expression, phosphorylation level and expression of p65, but it significantly increased IκBα level during IL-1β treatment ( Figure 5C ). TFEB also decreased phosphorylation of IKKα/β induced by IL-1β ( Figure 5C and Figure VII in the online-only Data Supplement), suggesting that IKK activity can be inhibited by TFEB. To test whether IKK mediates TFEB silencing-induced inflammation, we used IKK inhibitor PS-1145. TFEB knockdown increased phosphorylation levels of IKKα/β, IκBα, p65, and increased VCAM1 expression, which were all reversed by blockade of IKK activity ( Figure 5D and Figure VII in the online-only Data Supplement). IκBα level was lower in TFEB-silenced HUVECs; PS-1145 treatment increased IκBα level in both SCR-and shTFEB-treated HUVECs ( Figure 5D and Figure  VII in the online-only Data Supplement). Taken together, the present results demonstrate that TFEB inhibits NF-κB through suppression of IKK activity.
TFEB Attenuates IKK Signaling to Increase IκBα Level in db/db Mouse Aorta
To determine whether TFEB also regulates IKK-IκBα pathway in vasculature of db/db mice, we measured IKK and IκBα protein levels in aortas with in vivo and ex vivo TFEB treatment. Phosphorylated level of IKKα/β and IκBα in aortas of db/db mice was higher than that of db/m + mice accompanied by a reduced expression of IκBα ( Figure 6A and 6C). TFEB overexpression decreased levels of p-IKKα/β and p-IκBα and increased total IκBα expression in db/db mouse aortas ( Figure 6B and 6D) . These results further support that TFEB is an anti-inflammatory factor, which restrains IKK signaling to inhibit NF-κB activity in ECs. 
KLF2 Mediates LSS-Induced TFEB Upregulation in ECs
Exercise increases blood flow to benefit vascular health. LSS generated by the vaso-protective laminar flow in the straight part of blood vessel confers ECs an anti-inflammatory phenotype. 24 We subjected db/db mice to 3-week exercise on treadmills with a running speed of 10 meters/min for 30 minutes each day and found that TFEB is likely to be an exerciseresponsive factor as its mRNA level in aorta increased about 2-fold after exercise in db/db mice ( Figure 7A ). In addition, HUVECs exposed to LSS (12 dyn/cm 2 ) expressed a higher level of TFEB mRNA compared with static cells (Figure 7B) . Likewise, the protein expression and nuclear level of TFEB in HUVECs was also increased by LSS ( Figure 7C and 7D) .
Previous studies revealed KLF2 (Krüppel-like factor 2) is a shear stress-responsive factor that controls EC phenotype in response to LSS. 16 To test whether LSS-induced TFEB expression can be regulated by KLF2, we silenced KLF2 mRNA using Ad-shKLF2 in HUVECs exposed to LSS for 24 hours. Ad-shKLF2 abolished LSS-induced increases in TFEB mRNA and protein levels ( Figure 7E and 7F) , indicating that KLF2 expression is required for LSS-induced TFEB. To determine whether KLF2 can directly regulate TFEB expression, we used Ad-KLF2 overexpression to detect changes in TFEB mRNA and protein expression. Ad-KLF2 transduction to HUVECs for 24 hours significantly induced TFEB mRNA and protein expression ( Figure 7G and 7I) . Moreover, Ad-shKLF2 transduction reduced basal TFEB mRNA in HUVECs ( Figure 7J ), indicating that KLF2 is an endogenous inducer of TFEB. Luciferase reporter assay showed that KLF2 overexpression increased TFEB promoter activity in HUVECs transfected with TFEB promoter-luciferase reporter ( Figure 7H ). To determine whether TFEB is able to reverse KLF2 silencinginduced VCAM1 expression, we overexpressed TFEB in HUVECs treated with shKLF2 followed by LSS. As expected, TFEB overexpression reversed shKLF2-induced upregulation of VCAM1 in HUVECs exposed to LSS ( Figure 7K ). Taken together, TFEB induction by laminar flow is KLF2-dependent and mediates the anti-inflammatory effects of laminar flow and KLF2 in ECs.
Discussion
TFEB, a master regulator of lysosomal biogenesis, controls expression of a range of autophagy genes. 12, 13 The activity of TFEB is tightly controlled by metabolic signals. For example, energy-sufficient condition inactivates TFEB through mTORC1 (mechanistic target of rapamycin complex 1)-mediated phosphorylation although energy-deficient state promotes TFEB transcriptional activity. 25, 26 Cellular metabolism pathway has recently emerged to be a critical regulator of inflammatory progression. 27 Type 2 diabetes mellitus is a metabolic syndrome with dysregulated cellular metabolism and increased tissue inflammation. Our findings of the anti-inflammatory effect of TFEB through suppression of NF-κB activity in diabetic db/db mice reveal a new molecular mechanism bridging TFEB, a metabolically regulated factor, with inflammation.
Although TFEB is just recently known to inhibit endothelial inflammation, whether TFEB exerts anti-inflammatory effects on vasculature under diabetic condition and how TFEB regulates inflammatory pathway remains largely unexplored. In addition, the factor regulating TFEB expression in ECs under laminar flow is also unclear. The present study clearly shows that TFEB expression is mainly restricted to ECs and its activity is reduced in aortic endothelium of diabetic db/db mice. Overexpression of TFEB suppresses the expression of proinflammatory molecules. Using RNA-seq, we sought to identify key proinflammatory pathways that are regulated by TFEB and found that TFEB inhibits NF-κB activity to suppress the expression of proinflammatory genes such as VCAM1, ICAM1, SELE, and CCL2. Mechanistically, we reveal that TFEB suppresses IKK activity to upregulate IκBα level, leading to restrained nuclear translocation of p65. Finally, we identified KLF2 as a required upstream regulator of TFEB expression in ECs under laminar flow. Thus, the laminar flow-KLF2-TFEB signaling axis links the anti-inflammatory function of TFEB to physiological relevance.
We aimed to understand how endothelial TFEB activity is regulated under diabetic conditions. The present results show an EC-dominant expression of TFEB in mouse aorta and a diminished TFEB activity in diabetic mouse vascular endothelium. Our in vitro experiments also indicate that TFEB activity is repressed by diabetes mellitus-related factors such as IL-1β and insulin. Endothelial TFEB activity plays important roles in pathophysiological processes such as regulation of postischemic angiogenesis through activation of AMPK-α (AMP-activated protein kinase-α) and autophagy. 28 Uncovering the mediator(s) for reducing TFEB activity in diabetes mellitus will help uncover any unrecognized physiological properties of TFEB.
The present study shows a suppressed expression of VCAM1 and ICAM1 in diabetic mouse aortas overexpressed with TFEB. Our ex vivo organ culture data support that this anti-inflammatory effect is directly attributed to TFEB upregulation in aortas. Moreover, the plasma lipid profile was unchanged in Ad-GFP-and Ad-TFEB-treated db/db mice ( Figure  IV in the online-only Data Supplement), further confirming such anti-inflammatory effect is direct, but not secondary to altered blood proinflammatory lipoproteins. We notice that TFEB regulates lipid metabolism in hepatocytes. Therefore, we tried several time points to overexpress TFEB using adenoviral vectors before we finally used 5-day overexpression for observation of the vascular effect of TFEB. Adhesion of circulating monocyte to endothelium is a critical step in the initiation of vascular inflammation. 29 The inhibitory effect of TFEB on monocyte adhesion to HUVECs supports the in vivo results that TFEB inhibits inflammation in diabetic mouse aortas. In the present study, we only used male db/db mice to observe the anti-inflammatory function of TFEB. We tested the possible effect of estrogen on TFEB-mediated actions and found that the suppressive effect of TFEB on proinflammatory gene expression is not affected by estrogen treatment in HUVECs ( Figure II in the online-only Data Supplement). Therefore, we did not use female db/db mice to test the possible sex difference on TFEB-induced anti-inflammatory function.
We next sought to investigate the underlying mechanism of TFEB-mediated anti-inflammatory function. We used RNA-seq approach aiming to uncover genes with altered expression in HUVECs after TFEB overexpression. The RNAseq results showed that the expression of a great number of genes in NF-κB pathway was altered by TFEB. We verified the expression of several key NF-κB target genes by quantitative polymerase chain reaction and further confirmed the inhibitory effect of TFEB on NF-κB by luciferase assay. These observations prompted us to address how TFEB affects NF-κB activity. We screened 6 candidate target genes of TFEB and found that IKK activity can be inhibited by TFEB. Although we did not go further to show which gene(s) mediate the suppressive effect of TFEB on IKK, by using a combination of methods, we confirmed that the IKK-IκBα-p65 signaling axis is indeed regulated by TFEB.
Hyper-activation of NF-κB is well documented in multiple tissues including blood vessels in diabetes mellitus. Activation of NF-κB in ECs can be triggered by hyperglycemia, increased circulating proinflammatory cytokines, free fatty acids, and overproduced reactive oxygen species on vascular wall. 30 NF-κB activation at its early phase protects cells from death by upregulating key prosurvival genes such as BCL2 and SOD2; however, sustained activation of NF-κB results in tissue inflammation and remodeling. 31, 32 The present results show that TFEB activity is inhibited by diabetes mellitus-related molecule IL-1β, whereas TFEB itself is anti-inflammatory in diabetic mouse aortas. These findings suggest a reciprocal inhibition between NF-κB and TFEB in ECs. It is probable that TFEB may work as a balancing factor to regulate proinflammatory activation of ECs. Targeting TFEB using pharmacological agents may, therefore, hold promise against diabetic vascular inflammatory complications. The present results suggest that increased mTORC1 activity ( Figure I in the online-only Data Supplement) is likely to mediate inactivation of TFEB in diabetic mouse ECs. The activity of AMPK, a cellular energy sensor, is known to be decreased in diabetes mellitus and required for TFEB-induced expression of lysosomal genes in embryonic stem cells. We observed that AMPK activator metformin induces TFEB nuclear translocation in HUVECs ( Figure  I in the online-only Data Supplement). Therefore, AMPK may also be responsible for reduced TFEB activity in diabetes mellitus.
The vascular beneficial effect of physical exercise is well established. 33 TFEB was activated by physical exercise in muscle to promote metabolic flexibility. 34 The present study also demonstrates that TFEB is inducible in aortas of exercising db/db mice. Furthermore, we show that laminar flow induces TFEB expression through KLF2 although the detailed regulatory mechanism of TFEB induction by KLF2 is still unclear. KLF2 binds to 5′-CACCC-3′ DNA sequences in the gene promoter regions. 35 TFEB promoter contains several CACCC sequences within 2000 bp ahead of transcription start site. TFEB promoter activity assay showed that KLF2 induces TFEB promoter activation. Therefore, it is possible that KLF2 directly binds to TFEB promoter to activate TFEB mRNA transcription in ECs. Laminar flow and KLF2 confer ECs an anti-inflammatory phenotype. 16 The Figure 7 . KLF2 (Krüppel-like factor 2) mediates LSS (laminar shear stress)-induced TFEB (transcription factor EB) upregulation. A, The db/db mice were subjected to exercise on treadmill for 3 wk with a running speed of 10 m/min for 30 min each day, and the mRNA levels of Tfeb in isolated aortas were measured by quantitative polymerase chain reaction (qPCR), n=5 to 14. Human umbilical vein endothelial cells (HUVECs) were exposed to LSS (12 dyn/cm 2 ) for 24 h and the mRNA level of TFEB (B) were measured by qPCR (n=6) whereas the protein level of TFEB (n=5) was measured by Western blotting (C) and immunofluorescence (D). HUVECs were treated with KLF2 shRNA adenovirus (Ad-shKLF2) for 72 h and then exposed to LSS for 24 h; the mRNA (E) and protein (F) levels of TFEB were thereafter measured (n=8-9). HUVECs were treated with KLF2 adenovirus (Ad-KLF2) for 24 h, and the mRNA level (G), promotor activity (H), and protein (I) level of TFEB were then measured (n=6-8). HUVECs were treated with Ad-shKLF2 for 72 h, and the mRNA level of TFEB (J) were measured (n=6). HUVECs were treated with Ad-shKLF2 for 48 h and then with ad-TFEB for 24 h. Cells were then exposed to LSS for 24 h. The protein level VCAM1 (vascular cell adhesion molecule 1) was measured (K). L represents the schematic model for the anti-inflammatory effect of TFEB. E was analyzed by 1-way ANOVA followed by Tukey compare of variance. B, C, and G-J were analyzed by Mann-Whitney test. F and K were analyzed by Kruskal-Wallis test followed by Dunn compare of variance. GFP indicates green fluorescent protein; LPS, lipopolysaccharides; and mRNA, messenger RNA.
results suggest that TFEB is a key anti-inflammatory effector downstream of laminar flow and KLF2 because restoration of TFEB level in KLF2-silenced HUVECs recovered laminar flow-induced inhibition of proinflammatory gene expression. The cytoprotective and anti-inflammatory LSS serves as a switch to divert NF-κB from its proinflammatory branch to function as a cytoprotective factor. 36 Based on our results that TFEB inhibits NF-κB, it is worthwhile examining whether TFEB acts as a modulator to render NF-κB as a constant cytoprotective factor under laminar flow in future studies.
In summary, the present study provides the first line of evidence that TFEB inhibits vascular inflammation through suppressing NF-κB activity. This inhibitory effect of TFEB is attributed to both reduced IKK activity and increased IκBα level. Our study further reveals KLF2 as a previously unrecognized regulator of TFEB expression in ECs ( Figure 7L ). Thus, pharmacological activation of TFEB activity or expression may represent an effective approach against vascular inflammation and dysfunction in diabetes mellitus.
